Ayesha Munir, MD
Hematology & Oncology · Mobile, ALNPI 1386174563
Payments from drug & device makers
Across 118 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$615
- Johnson & Johnson$294
- Incyte Corporation$198
- Daiichi Sankyo Inc.$181
- Regeneron Healthcare Solutions, Inc.$163
- Eisai Inc.$123
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,19774%
- Education$2549%
- Other$49917%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $615 |
| Johnson & Johnson | 14 | $294 |
| Incyte Corporation | 3 | $198 |
| Daiichi Sankyo Inc. | 9 | $181 |
| Regeneron Healthcare Solutions, Inc. | 6 | $163 |
| Eisai Inc. | 7 | $123 |
| Tersera Therapeutics LLC | 5 | $116 |
| EMD Serono, Inc. | 4 | $93 |
| AbbVie | 3 | $87 |
| Merck | 4 | $82 |
| Bristol Myers Squibb | 3 | $78 |
| Pfizer | 2 | $76 |
| Gilead | 4 | $74 |
| Immunocore Limited | 3 | $66 |
| Genmab U.S., Inc. | 4 | $62 |
| Pharmaessentia USA Corporation | 3 | $55 |
| Genentech USA, Inc. | 3 | $55 |
| Cumberland Pharmaceuticals, Inc. | 3 | $49 |
| Sobi, Inc | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| AstraZeneca | 2 | $37 |
| Boehringer Ingelheim | 2 | $37 |
| Taiho Oncology, Inc. | 2 | $33 |
| Beone Medicines USA, Inc. | 2 | $31 |
| Blueprint Medicines Corporation | 1 | $28 |
| Agios Pharmaceuticals, Inc. | 1 | $24 |
| Array Biopharma Inc | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Exelixis Inc. | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $19 |
| Sanofi | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Beigene USA, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Deciphera Pharmaceuticals Inc. | 1 | $15 |
| Bayer | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
How this compares
$2,950 in reported general payments places this provider in the 25th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 82 | $1,152 |
| Tamoxifen Citrate | 13 | $648 |
| Letrozole | 20 | $474 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Mobile
- Michael MeshadMobile$5.3M
- Jose Galeas SorianoMobile$536K
- Anita MazloomMobile$454K
- Sherri ArledgeMobile$358K
- Brian HellerMobile$213K
- Thaddeus BeekerMobile$195K
- Prajwol PathakMobile$158K
- Ahmed AbdallaMobile$141K
- Luciano CostaBirmingham$32.8M
- Amitkumar MehtaBirmingham$18.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.